Litcius/Paper detail

Gene therapy for retinitis pigmentosa

Niloofar Piri, Jacob D. Grodsky, Henry J. Kaplan

2021Taiwan Journal of Ophthalmology24 citationsDOIOpen Access PDF

Abstract

Rhodopsin-mediated autosomal dominant retinitis pigmentosa (RP) is the most common cause of RP in North America. There is no proven cure for the disease, and multiple approaches are being studied. Gene therapy is an evolving field in medicine and ophthalmology. In this review, we will go over the basic concept of gene therapy and the different types of gene therapy that are currently being studied to treat this disease.

Topics & Concepts

Retinitis pigmentosaMedicineGenetic enhancementDiseaseGeneOphthalmologyBioinformaticsGeneticsInternal medicineRetinalBiologyRetinal Development and DisordersCRISPR and Genetic EngineeringVirus-based gene therapy research
Gene therapy for retinitis pigmentosa | Litcius